ASH 2018 | Off-the-shelf CAR T-cell therapy
Dietmar Berger
• 7 Jan 2019
In this interview, Dietmar Berger, MD, PhD, of Atara Biotherapeutics, San Francisco, CA, discusses the current limitations of CAR T-cells. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Berger introduces the exciting next generation, off-the-shelf CAR T-cell products, which can be utilized in the allogeneic setting. Dr Berger talks through the many advantages of this, before revealing the use of these CAR T-cells, notably in B-cell malignancies and acute myeloid leukemia (AML).
